Jane Street’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-21,400
Closed -$215K 12308
2025
Q3
$215K Sell
21,400
-21,000
-50% -$301K ﹤0.01% 9539
2025
Q2
$740K Buy
42,400
+2,800
+7% +$40.4K ﹤0.01% 6192
2025
Q1
$498K Buy
+39,600
New +$476K ﹤0.01% 6871
2024
Q4
Sell
-39,900
Closed -$579K 10519
2024
Q3
$579K Buy
+39,900
New +$475K ﹤0.01% 6937
2023
Q3
Sell
-12,600
Closed -$84.4K 9341
2023
Q2
$84.4K Buy
+12,600
New +$84.1K ﹤0.01% 8069

Other funds holding SPRY

Jane Street's SPRY Position: Q4 2025 in Review

Jane Street sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 242,037 shares — an estimated $2.35M sold.

Jane Street first reported a position in SPRY in Q4 2020 and held it in 13 quarters. The position peaked at $2.43M in Q3 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Jane Street reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 242,037 ARS Pharmaceuticals shares in Q4 2025, an estimated $2.35M.
  • Jane Street first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • Jane Street's ARS Pharmaceuticals position peaked at $2.43M in Q3 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.